Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- cell therapy
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245950
The patents are regarding manufacturing method and Polymorphism and combination use.
The Product shall mean any therapeutic or preventative pharmaceutical products containing the Compound as an ingredient.
The Compound shall mean the compound known as TM-411 (Tamibarotene), and any parts, analogs and derivatives thereof.
The trademark shall mean OSALEUKIN.
Field 2 shall mean the pharmaceutical prevention or treatment in human hematological malignancies, including but not limited to Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia (CMMoL), Chronic Myelocytic leukemia (CML) and Acute myelocytic leukemia (AML) and solid tumor indications except Hepatocelluar carcinoma (HCC). Field shall collectively mean Field 1 and Field 2.
IPSCIO Record ID: 245951
The licensed patents refer to manufacturing method for preparing benzoic acid derivatives and Polymorphism.
Product shall mean any therapeutic or preventative pharmaceutical product made from or comprising Technology for human use in the Field.
Field 2 shall mean the pharmaceutical prevention or treatment in humans of the following indications multiple myeloma (MM), myelodysplatic syndrome (MDS), and all solid tumor indications and Field shall collectively mean Field 1 and Field 2.
IPSCIO Record ID: 3282
Licensee field is diagnostics in Multiple myeloma, or MM, a hematologic, or blood, cancer that develops in the bone marrow and specifically affects the plasma cells of the bone marrow.
The Licensee Licensed field includes applications to malignant and non-malignant human or animal pathologies, including but not limited to determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen. These uses, patent, and technology rights exclude using FISH, which is Licensed to a third party.
IPSCIO Record ID: 360156
Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).
IPSCIO Record ID: 26488
IPSCIO Record ID: 359061
With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.
Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.
NLG919 means Licenseeâ€™s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.
Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.
IPSCIO Record ID: 344510
Licensor grants an exclusive license. with the right to grant sublicenses through multiple tiers of Sublicensees. to use the Licensor Trademarks on or in connection with the commercialization of the Licensed Product in the Licensed Territory in the Licensed Field.
The trademark is ESTYBON.
Rigoscrtib is a novel targeted anti-cancer compound currently in a Phase Ill study for the treatment of a group of rare hematologic malignancies called /.1yelodysp!astic Syndromes (MOS) and in a Phase II/Ill study for pancreatic cancer.
The Compound means the substance that is a sodium salt of (E)-2,4,6-trimethoxystyryl-3 carboxymethylamino-4-methoxybenzyl sulfone, or any Derivative/Improvement thereof.
The Patents include among others
Amino substituted sulfones treating proliferative disorders, and,
Composition and Methods for Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia.
IPSCIO Record ID: 372435
Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.
Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.
DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.
DART Platform means Licensors proprietary platform for generating DARTs.
Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.
Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.
xx-011 is a humanized CD19 x CD3 bispecific DART protein.
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.
The patents include
— Covalent Diabodies And Uses Thereof;
— Covalent Diabodies And Uses;
— Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
— CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
— Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.
The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans. This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.